Singapore HSA Medical Device Registration Consultants

Singapore HSA medical device registration is the legal gateway to one of Asia’s most respected healthcare markets. Medfins International helps manufacturers in India and overseas classify their devices, choose the right HSA evaluation route, build an ASEAN CSDT dossier and work with a Singapore registrant so that submissions reach the Health Sciences Authority complete and review-ready.

What is Singapore HSA medical device registration?

The Health Sciences Authority (HSA) regulates medical devices under the Health Products Act and the Health Products (Medical Devices) Regulations 2010. Before a Class B, C or D device can be supplied in Singapore, it must be listed on the Singapore Medical Device Register (SMDR) through product registration.

Registration sits alongside two other controls: a product notification regime for most Class A devices, and dealer’s licences for companies that manufacture, import or wholesale devices. A reviewer will expect all three to line up.

Who needs HSA registration?

• Overseas manufacturers, including Indian manufacturers, that want to sell in Singapore. They must work through a locally incorporated company that acts as the registrant.
• Singapore importers and distributors acting as registrant for the brands they carry.
• Local manufacturers placing their own devices on the market.

The registrant is legally responsible for the registration, for post-market duties such as field safety corrective actions and adverse event reporting, and for keeping the listing current when the device changes.

Classification and scope

HSA uses a four-tier risk classification closely aligned with the ASEAN Medical Device Directive (AMDD) and IMDRF principles. Separate rule sets apply to general medical devices and to IVDs.

• Class A (low risk) – exempt from product registration. Most Class A devices require a product notification so that they appear in HSA’s Class A medical device database; certain Class A devices are fully exempt.
• Class B (low-moderate risk) – product registration required.
• Class C (moderate-high risk) – product registration required.
• Class D (high risk) – product registration required, with the deepest review.

Getting the class right is the most important early decision, because it fixes the evaluation route, the dossier depth and the review time.

HSA evaluation routes

For Class B, C and D devices, HSA offers several routes depending on prior approvals from its overseas reference regulatory agencies:

• Full evaluation – for devices without a qualifying reference approval, for example a device first launched in India.
• Abridged evaluation – where the device holds approval from at least one reference agency.
• Expedited routes – for Class C and D devices meeting set conditions, such as multiple reference approvals and, for some routes, a safe marketing history.
• Immediate routes – for qualifying Class B and C devices that meet HSA’s reference-approval and safety conditions.

Route eligibility rules are detailed and change from time to time, so we confirm them against current HSA guidance for each device.

Documents required

HSA accepts technical dossiers in the ASEAN Common Submission Dossier Template (CSDT) format, and also IMDRF table-of-contents formats for some submissions. A typical dossier includes:

• Letter of authorisation from the product owner to the Singapore registrant
• Device description, intended purpose, indications and variants
• Essential principles checklist and declaration of conformity
• ISO 13485 certificate and evidence of the manufacturing sites
• Risk management file summary to ISO 14971
• Design verification and validation: biocompatibility, electrical safety and EMC, software validation, sterilisation and shelf-life data as relevant
• Clinical evidence appropriate to the class
• Labels, instructions for use and the proposed Singapore labelling
• Reference agency approvals and post-market history, where claiming an abridged, expedited or immediate route

Registration process

1. Regulatory assessment – confirm the product is a medical device, determine its class and check route eligibility.
2. Appoint the registrant – agree roles with a Singapore company that holds, or will hold, the necessary dealer’s licences.
3. Gap analysis – compare existing technical files (for example CE or FDA files) against HSA’s CSDT expectations.
4. Dossier preparation – compile and cross-check the CSDT, labelling and supporting evidence.
5. Submission – file through HSA’s online system. HSA moved medical device e-services from MEDICS to its new SHARE portal in July 2025.
6. Screening and evaluation – respond to HSA queries within the stated deadlines.
7. Listing on the SMDR – after approval, maintain the registration, manage change notifications and pay annual retention fees.

Dealer’s licences and GDPMDS

Registration covers the product; the business also needs licences. Companies that manufacture, import or wholesale medical devices in Singapore generally need the relevant dealer’s licence. Importers and wholesalers are typically expected to hold certification to Good Distribution Practice for Medical Devices (GDPMDS, SS 620), while local manufacturers normally show ISO 13485 certification. Our ISO 13485 support helps manufacturers meet the quality system side.

Timelines and what affects them

HSA publishes target turnaround times for each class and route, counted in working days and excluding the time the applicant spends answering queries. Per HSA’s published targets, an abridged or full evaluation typically runs from several months to over a year, while immediate routes are approved on submission when all conditions are met. The main drivers are:

• Device class and the route you qualify for
• Completeness and consistency of the dossier
• Speed and quality of query responses
• Number of models, variants and accessories grouped in one application

Common reasons for delays and queries

• Incorrect classification, especially for software, IVDs and accessories
• Claiming a route without the right reference approvals or with mismatched intended use
• Labels and instructions for use that differ from what the reference agency approved
• Outdated test reports or standards no longer considered current
• Weak clinical evidence for Class C and D devices
• Registrant or dealer’s licence arrangements not in place at submission

How Medfins International supports you

Medfins International has delivered more than 175 regulatory projects across 15+ countries. Our team is led by a CQI and IRCA certified ISO 13485 Lead Auditor, so dossier work is grounded in how quality systems are actually audited.

• Classification rationale and evaluation route strategy
• CSDT dossier preparation, reuse of CE marking and US FDA 510(k) evidence where it fits
• Coordination with your Singapore registrant and query management
• Planning for other ASEAN markets such as Malaysia MDA using the same CSDT core

To discuss your device and route, contact our regulatory team.

Frequently asked questions